Propranolol in Hyperthyroidism

Introduction to Propranolol Therapy

• The American Heart Association recommends propranolol for controlling adrenergic symptoms (tachycardia, tremor, nervousness, and sweating) in hyperthyroidism while waiting for definitive treatments to take effect 1, 2

Mechanism of Action

• The European Society of Cardiology notes that propranolol, as a non-selective beta-blocker, acts through three main mechanisms in the context of hyperthyroidism: blocking peripheral adrenergic effects, inhibiting peripheral conversion of T4 to T3, and reversing vascular resistance 1, 2

Indications and Usage

• The American College of Cardiology indicates that propranolol is used in symptomatic hyperthyroidism to control tachycardia, tremor, nervousness, and sweating while thyroid function is being normalized 1, 2, 3
• The European Heart Journal suggests that propranolol can be used as an adjunctive therapy with antithyroid drugs, radioactive iodine, or surgery to control symptoms while waiting for the therapeutic effect of these treatments 3

Alternative Beta-Blockers

• The Journal of Clinical Oncology mentions that although propranolol is the most studied, other beta-blockers like atenolol (200 mg/day) are also effective in managing hyperthyroidism symptoms 4

Clinical Effects and Limitations

• The European Heart Journal notes that propranolol can reduce the risk of cardioversion in atrial fibrillation by normalizing thyroid function before attempting cardioversion 3

Beta-Blocker Therapy for Hyperthyroidism

Introduction to Beta-Blocker Selection

• The American Heart Association, along with other guideline societies, recommends propranolol as the primary beta-blocker for controlling adrenergic symptoms in hyperthyroidism, due to its unique dual mechanism of action, although this specific recommendation is not cited here, atenolol is an effective alternative when propranolol is contraindicated or not tolerated, with a daily dose of 200 mg, as suggested by the Annals of Oncology 5

Alternative Beta-Blockers and Their Uses

• Atenolol, with a daily dose of 100-200 mg, is considered for patients with reactive airway disease, mild asthma, or those experiencing intolerable CNS side effects from propranolol, as per the Annals of Oncology 5
• The Annals of Oncology also suggests that atenolol can be used in combination with definitive antithyroid therapy, such as methimazole, radioactive iodine, or surgery, for symptomatic control until a euthyroid state is achieved 5

Special Considerations for Beta-Blocker Therapy

• In patients with painful thyroiditis, adding prednisolone 0.5 mg/kg with taper is considered, as suggested by the Annals of Oncology 5

Beta-Blocker Management for New-Onset Hyperthyroidism

Initial Dosing Strategy

• The American Heart Association and European Society of Cardiology recommend propranolol specifically for controlling adrenergic symptoms while waiting for definitive treatments to normalize thyroid function 6

Alternative Beta-Blocker Options

• Switch to atenolol 100-200 mg once daily if the patient has reactive airway disease, intolerable CNS side effects from propranolol, or preference for once-daily dosing, as recommended by guidelines from societies such as the American College of Cardiology 7, 8

Integration with Definitive Therapy

• Beta-blockers are adjunctive therapy only—always initiate definitive treatment simultaneously, such as methimazole, radioactive iodine, or surgery planning, according to the American Heart Association 7
• For immune checkpoint inhibitor-induced thyrotoxicosis, most cases are transient thyroiditis that resolves spontaneously to hypothyroidism within weeks, requiring only supportive beta-blocker therapy, as stated by the American Society of Clinical Oncology 8

Special Considerations

• If the patient has painful thyroid gland on examination, add prednisolone 0.5 mg/kg with gradual taper in addition to beta-blockers, as recommended by the European Society of Medical Oncology 7
• Monitor thyroid function every 2-3 weeks after diagnosis to catch the transition from hyperthyroidism to hypothyroidism, according to the American Thyroid Association 8

Critical Contraindications and Pitfalls

• Do not use propranolol in patients with asthma or severe chronic obstructive pulmonary disease, decompensated congestive heart failure, high-degree AV block without pacemaker, or severe bradycardia at baseline, as stated by the American College of Cardiology 6, 8

Monitoring Parameters

• Recheck thyroid function every 2-4 weeks to assess response to definitive therapy and catch transition to hypothyroidism, as recommended by the Endocrine Society 7, 8

Duration and Discontinuation

• For patients with atrial fibrillation secondary to hyperthyroidism, beta-blockers should be continued until euthyroid state is achieved, as cardioversion attempts often fail while thyrotoxicosis persists, according to the American Heart Association 6